<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258388</url>
  </required_header>
  <id_info>
    <org_study_id>I165</org_study_id>
    <secondary_id>CAN-NCIC-IND165</secondary_id>
    <secondary_id>ONCOGENEX-OGX-011-03</secondary_id>
    <secondary_id>FHCRC-6084</secondary_id>
    <secondary_id>UWCC-UW-6084</secondary_id>
    <secondary_id>UWCC-06-0499-H/D</secondary_id>
    <secondary_id>CDR0000450846</secondary_id>
    <nct_id>NCT00258388</nct_id>
  </id_info>
  <brief_title>Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy</brief_title>
  <official_title>A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor&#xD;
      cells less resistant to the drugs.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving docetaxel and prednisone&#xD;
      with or without OGX-011 works in treating patients with recurrent or metastatic prostate&#xD;
      cancer that did not respond to previous hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy, in terms of prostate-specific antigen response, of docetaxel and&#xD;
           prednisone with or without OGX-011 in patients with hormone-refractory locally recurrent&#xD;
           or metastatic prostate cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the objective response rate and duration in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Determine the safety and toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Determine the overall and progression-free survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, open-label study. Patients are randomized to 1 of&#xD;
      2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive a loading dose of OGX-011 IV over 2 hours on days -7, -5, and&#xD;
           -3. Patients then receive OGX-011 IV over 2 hours on days 1, 8, and 15, docetaxel IV&#xD;
           over 1 hour on day 1, and oral prednisone twice daily on days 1-21. Treatment repeats&#xD;
           every 3 weeks for up to 10 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel IV over 1 hour on day 1 and oral prednisone twice&#xD;
           daily on days 1-21. Treatment repeats every 3 weeks for up to 10 courses in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2005</start_date>
  <completion_date type="Actual">January 18, 2011</completion_date>
  <primary_completion_date type="Actual">November 8, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) response measured by Bubley criteria at completion of study</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>OGX011, Docetaxel and Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel plus prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>custirsen sodium</intervention_name>
    <description>640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)&#xD;
Subsequent cycles:&#xD;
weekly on days 1, 8, 15 (3 week cycles)</description>
    <arm_group_label>OGX011, Docetaxel and Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)</description>
    <arm_group_label>Docetaxel plus prednisone</arm_group_label>
    <arm_group_label>OGX011, Docetaxel and Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>5mg PO BID</description>
    <arm_group_label>Docetaxel plus prednisone</arm_group_label>
    <arm_group_label>OGX011, Docetaxel and Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic or locally recurrent disease&#xD;
&#xD;
          -  Not curable with standard therapy&#xD;
&#xD;
          -  Systemic chemotherapy is indicated, due to disease progression while receiving&#xD;
             androgen-ablative therapy (i.e., hormone-refractory disease)&#xD;
&#xD;
               -  Disease progression is defined as development of new metastatic lesions OR ≥ 2&#xD;
                  consecutive rises in prostate-specific antigen (PSA) over a reference value&#xD;
&#xD;
               -  Androgen ablative therapy must have included either medical or surgical&#xD;
                  castration&#xD;
&#xD;
                    -  Castrate level of testosterone (≤ 1.7 nmol/L) required if treated with&#xD;
                       medical androgen ablation&#xD;
&#xD;
               -  Patients with documented disease progression while on peripheral antiandrogens&#xD;
                  must also have documented PSA progression after stopping antiandrogens&#xD;
&#xD;
          -  PSA ≥ 5 ng/mL&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No known bleeding disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  PT and PTT or INR normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiac dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
          -  No significant neurological disorder that would preclude study compliance&#xD;
&#xD;
          -  No history of other malignancies within the past 5 years except adequately treated&#xD;
             nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy except estramustine and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior antiandrogens (6 weeks for bicalutamide)&#xD;
&#xD;
          -  Luteinizing hormone-releasing hormone (LHRH) agonist therapy must be continued* or&#xD;
             restarted* during study treatment to maintain castrate levels of testosterone NOTE:&#xD;
             *For patients receiving LHRH agonist therapy prior to study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior external beam radiotherapy except low-dose,&#xD;
             nonmyelosuppressive radiotherapy&#xD;
&#xD;
               -  Must have had less than 25% of marrow irradiated&#xD;
&#xD;
          -  No prior strontium chloride Sr 89&#xD;
&#xD;
          -  No concurrent radiotherapy except low-dose, nonmyelosuppressive, palliative&#xD;
             radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agent&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer therapy&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulants except low-dose oral anticoagulants (i.e., 1&#xD;
             mg warfarin) or low molecular weight heparin&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim N. Chi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23.</citation>
    <PMID>20733135</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

